Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial

Citations Over TimeTop 13% of 2019 papers

Abstract

First-line treatment of pemphigus with rituximab results in a slightly greater cost compared with a standard CS regimen. What's already known about this topic Rituximab is the most effective treatment for moderate-to-severe pemphigus. Rituximab cost might be considered as a limitation of this treatment. What does this study add? After 3 years of follow-up, mean individual total cost for a patient with first-line treatment with rituximab was €14 818 vs. €13 997 with standard corticosteroids (CS), resulting in a slightly higher cost of €821 (+6%). The initially greater cost of rituximab was counterbalanced by costs related to management of flares/relapses in patients treated with a standard CS regimen.

Related Papers

• → Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab(2017)34 cited
• [Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].(2013)
• → A COMMON ERROR IN USING COMBINED TREATMENT WITH RITUXIMAB AND PLASMAPHERESIS (PP) TO PREVENT OR TREAT ANTIBODY MEDIATED REJECTION (AMR)(2020)
• [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].(2013)
• → Treatment: Rituximab(2018)